146 related articles for article (PubMed ID: 33016814)
1. Cost-utility analysis of newborn hepatitis B immunization in Beijing.
Guo Y; Yang Y; Bai Q; Huang Z; Wang Z; Cai D; Li S; Man X; Shi X
Hum Vaccin Immunother; 2021 Apr; 17(4):1196-1204. PubMed ID: 33016814
[TBL] [Abstract][Full Text] [Related]
2. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
3. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
[No Abstract] [Full Text] [Related]
4. [Cost-effectiveness and cost-benefit analysis on strategy for preventing mother-to-child transmission of hepatitis B virus].
Cai YL; Zhang SX; Yang PC; Lin Y
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Jun; 37(6):846-51. PubMed ID: 27346114
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis.
Mokhtari AM; Barouni M; Moghadami M; Hassanzadeh J; Dewey RS; Mirahmadizadeh A
Hum Vaccin Immunother; 2021 Jun; 17(6):1825-1833. PubMed ID: 33734949
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.
Zeng Y; Luo M; Lin J; He H; Deng X; Xie S; Fang Y
Hum Vaccin Immunother; 2020 Apr; 16(4):955-964. PubMed ID: 31769718
[No Abstract] [Full Text] [Related]
7. Post-vaccination serologic testing of infants born to hepatitis B surface antigen-positive mothers is more cost-effective in Zhejiang Province, China: A Markov chain analysis.
Lu Z; Zhou Y; Yan R; Deng X; Tang X; Zhu Y; Xu X; Zheng W; He H
J Viral Hepat; 2022 Apr; 29(4):280-288. PubMed ID: 35075747
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness.
Harris A; Yong K; Kermode M
Aust N Z J Public Health; 2001 Jun; 25(3):222-9. PubMed ID: 11494989
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
[TBL] [Abstract][Full Text] [Related]
11. Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.
Carlos F; Gómez JA; Anaya P; Romano-Mazzotti L
Hum Vaccin Immunother; 2016; 12(1):52-63. PubMed ID: 26503702
[TBL] [Abstract][Full Text] [Related]
12. [Economic evaluation of various hepatitis B vaccination Strategies in Switzerland].
Zurn P; Danthine JP
Soz Praventivmed; 1998; 43 Suppl 1():S61-4, S134-7. PubMed ID: 9833269
[TBL] [Abstract][Full Text] [Related]
13. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of universal newborn hepatitis B vaccination in China.
Lu SQ; McGhee SM; Xie X; Cheng J; Fielding R
Vaccine; 2013 Apr; 31(14):1864-9. PubMed ID: 23384752
[TBL] [Abstract][Full Text] [Related]
15. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
Krahn M; Detsky AS
Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
[TBL] [Abstract][Full Text] [Related]
16. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.
Aggarwal R; Ghoshal UC; Naik SR
J Hepatol; 2003 Feb; 38(2):215-22. PubMed ID: 12547411
[TBL] [Abstract][Full Text] [Related]
17. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the national Perinatal Hepatitis B Prevention Program.
Barbosa C; Smith EA; Hoerger TJ; Fenlon N; Schillie SF; Bradley C; Murphy TV
Pediatrics; 2014 Feb; 133(2):243-53. PubMed ID: 24394684
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of hepatitis A vaccination in Indonesia.
Suwantika AA; Beutels P; Postma MJ
Hum Vaccin Immunother; 2014; 10(8):2342-9. PubMed ID: 25424941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
